EHA 2019: Results of a phase II study investigating obinutuzumab in combination with chemotherapy followed by autologous stem cell transplant for first line treatment of mantle cell lymphoma.
EHA 2019: Results of a phase II study investigating obinutuzumab in combination with chemotherapy followed by autologous stem cell transplant for first line treatment of mantle cell lymphoma.